Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit (Q35858331)
Jump to navigation
Jump to search
scientific article published on 31 March 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit |
scientific article published on 31 March 2014 |
Statements
1 reference
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit (English)
1 reference
Ignacio Wistuba
1 reference
Hartmut Koeppen
1 reference
Wei Yu
1 reference
Jiping Zha
1 reference
Ajay Pandita
1 reference
Elicia Penuel
1 reference
Linda Rangell
1 reference
Rajiv Raja
1 reference
Sankar Mohan
1 reference
Rajesh Patel
1 reference
Rupal Desai
1 reference
Ling Fu
1 reference
An Do
1 reference
Vaishali Parab
1 reference
Xiaoling Xia
1 reference
Tom Januario
1 reference
Sharianne G Louie
1 reference
Ellen Filvaroff
1 reference
David S Shames
1 reference
Marina Lipkind
1 reference
Jenny Huang
1 reference
Mirella Lazarov
1 reference
Vanitha Ramakrishnan
1 reference
Lukas Amler
1 reference
See-Chun Phan
1 reference
Premal Patel
1 reference
Amy Peterson
1 reference
Robert L Yauch
1 reference
31 March 2014
1 reference
1 reference
4488-4498
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference